Interim Report Q1 2025

10 Apr 2025 08:34 CEST

The Interim report for Q1 2025 for Induct AS has been approved by the Board of
Directors.

The results from the first quarter of 2025 show clear improvements in
profitability, and we have made significant strides toward becoming a more
efficient and scalable organization.

- EBITDA increased to NOK 3,0 in Q1 2025 from NOK 2,4 million in Q1 2024.

- Total operating costs reduced to NOK 1,9 million in Q1 2025 from NOK 3,1
million in Q1 2024.

- Gross margin on platform revenues at 96,8%.

- The Swedish version of Tilskuddsportalen, hittabidrag.se, was launched on 26
February with three subscription contracts already signed and a strong sales
pipeline consisting of individual municipalities and collaborative networks.

- Our collaboration with Portsmouth and AstraZeneca is progressing well and
according to plan. The hospital roll-out plan has been agreed, and Winchester
Hospital will be the first hospital to implement our asthma pathway product.

We are focused on and dedicated to increasing revenues to strengthen our EBITDA
further and deliver solid financial results.

For further information, please contact:
Synnøve Jacobsen
CEO
M: +47 99 41 54 47
E: sj@induct.net

More information:
Access the news on Oslo Bors NewsWeb site

643397_Induct - Interim Report Q1 2025.pdf